-
Loading metrics
A single-arm, open-label, phase 2 clinical trial evaluating disease response following treatment with BI-505, a human anti-intercellular adhesion molecule-1 monoclonal antibody, in patients with smoldering multiple myeloma
- Stina Wichert,
- Gunnar Juliusson,
- Åsa Johansson,
- Elisabeth Sonesson,
- Ingrid Teige,
- Anna Teige Wickenberg,
- Björn Frendeus,
- Magnus Korsgren,
- Markus Hansson

x
- Published: February 3, 2017
- https://doi.org/10.1371/journal.pone.0171205